Alkem Labs Agrees to Rs 1,100 Crore Medtech Acquisition of Occlutech Holding AG
Alkem Laboratories Limited (NSE: ALKEM, BSE: 539523) has announced a strategic acquisition that marks its entry into the global medical devices business. The company, through its wholly owned subsidiary Alkem Medtech Private Limited, has signed an agreement to acquire a majority stake in Occlutech Holding AG for approximately ₹1,100 crore.
The transaction represents a significant milestone in Alkem’s diversification strategy, expanding its presence beyond pharmaceuticals into the high-growth medical technology sector.
Acquisition Highlights
- Acquirer: Alkem Medtech Private Limited (wholly owned subsidiary of Alkem Laboratories)
- Target Company: Occlutech Holding AG
- Stake to be Acquired: Between 51% and 55% of the issued equity share capital
- Transaction Value: Approximately ₹1,100 crore
- Mode of Payment: Cash consideration
- Expected Completion: Equity shares are expected to be allotted by July 15, 2026, subject to the terms of the agreement and regulatory approvals.
Strategic Expansion into Medical Devices
The acquisition aligns with Alkem’s long-term strategy of building a strong presence in the medical technology industry.
Alkem Medtech, incorporated in March 2024, focuses on the cardiovascular and orthopedic medical device segments. By acquiring a controlling stake in Occlutech Holding AG, the company aims to strengthen its capabilities, broaden its product portfolio, and expand its global footprint in advanced medical devices.
Why the Deal Matters
The acquisition offers several strategic benefits:
- Diversifies Alkem’s business beyond pharmaceuticals.
- Establishes a stronger presence in the fast-growing global medical devices market.
- Expands the company’s healthcare portfolio across pharmaceuticals and medical technology.
- Creates opportunities for technology sharing, innovation, and long-term growth.
- Strengthens Alkem’s position in specialized cardiovascular and orthopedic solutions.